Drug intelligence / Profile preview

FC718

Development stage: Preclinical
Lead developer: FindCure Biosciences
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FC718 (also known as 88Ga/177Lu-FC718 or 68Ga/177Lu-FC718) is a preclinical-stage radionuclide-drug conjugate (RDC) being developed by FindCure Biosciences for the diagnosis and treatment of solid tumors. Developed using FindCure's proprietary InnoRDC platform, the agent is designed as a theranostic pair, utilizing gallium-68 (or gallium-88) for positron-emission tomography (PET) imaging/diagnosis and lutetium-177 for targeted radioligand therapy. The biological target of FC718 remains undisclosed by the developer.

Other names: 177Lu-FC71868Ga-FC71888Ga/177Lu-FC718Gallium 68 labeled FC-718Gallium68 labeled FC-718Gallium-68 labeled FC-718Gallium-68 FC 718Gallium68 FC 718Gallium 68 FC 718

Beyond the preview

Go deeper on FC718.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FC718.

Explore the full profile